Please login to the form below

Not currently logged in
Email:
Password:

EUSA Pharma adds William Crouse to board of directors

Comes as firm hopes to become global leader in biotechnology

EUSA Pharma has appointed William Crouse to its board of directors.

Crouse joins with 50 years of experience in the life sciences industry with his most recent role being general partner at Healthcare Venture, one of the world's largest venture capital firms specialising in biotechnology.

Prior to this, in his many roles over 30 years he has worked in the diagnostics industry, international operations, strategic planning, acquisitions, new product development and sales and marketing.

He said: “It's an honour to join EUSA and to help this ambitious company become a major force in the speciality field.

“Having worked with many of the EUSA team previously, I am confident the company has the capabilities and infrastructure in place to rapidly become a leading player in the sector.”

Bryan Morton, executive chairman at EUSA Pharma, said: “We have great ambitions for EUSA, and plan to grow our existing profitable business through acquisition and in-licensing.

“Bill's extensive experience and strategic insight will be a huge asset as we transform our business into a leading transatlantic speciality commercialization company.”

9th September 2015

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
W2O Group

W2O Group is an integrated marketing agency with expertise in brand and digital strategy, creative development and communications services. We...

Latest intelligence

“Fake News” and Credibility in Medical Publishing
Natalie Yeadon from Impetus Digital shares her thoughts on fighting fake news in Pharma and healthcare....
Delivering true value: what does it mean for KAM in cancer care?
Lisa Alderson, Business Development Director at Wilmington Healthcare, explores the challenges that pharma’s KAM teams face in engaging with the NHS and how they must evolve...
Pharma M&A
Pharma funding and M&A in 2020
Why pharma M&A has continually bucked the trend...

Infographics